A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds
Gallant-Behm CL, Piper J, Dickinson BA, Dalby CM, Pestano LA, Jackson AL. Wound Repair Regen. 2018 Aug 17. PubMed
Studies of Impending Oligonucleotide Therapeutics in Simulated Biofluids
Domljanovic I, Hansen AH, Hansen LH, Klitgaard JK, Taskova M, Astakhova K. Nucleic Acid Ther. 2018 Aug 14. PubMed
Characterization of the Activity and Distribution of a 2′-O-Methoxyethyl-modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease
Donner AJ, Bell TA, Greenlee S, Graham MJ, Crooke RM. Nucleic Acid Ther. 2018 Aug 22. PubMed
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
Janas MM, Harbison CE, Perry VK, Carito B, Sutherland JE, Vaishnaw AK, Keirstead ND, Warner G. Toxicol Pathol. 2018 Aug 23:192623318792537. PubMed
A Semi-mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
Biliouris K, Gaitonde P, Yin W, Norris DA, Wang Y, Henry S, Fey R, Nestorov I, Schmidt S, Rogge M, Lesko LJ, Trame MN. CPT Pharmacometrics Syst Pharmacol. 2018 Jul 24. PubMed
Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain
Toonen LJA, Casaca-Carreira J, Pellisé-Tintoré M, Mei H, Temel Y, Jahanshahi A, van Roon-Mom WMC. Nucleic Acid Ther. 2018 Apr;28(2):63-73. PubMed
The Evaluation of Pharmacodynamics and Pharmacokinetics of Anti-thrombin DNA Aptamer RA-36
Zavyalova E, Samoylenkova N, Revishchin A, Turashev A, Gordeychuk I, Golovin A, Kopylov A, Pavlova G. Front Pharmacol. 2017 Dec 14;8:922. PubMed
